Brivaracetam for the treatment of epilepsy

KLEIN, Pavel, Ivana TYRLÍKOVÁ, Milan BRÁZDIL and Ivan REKTOR. Brivaracetam for the treatment of epilepsy. EXPERT OPINION ON PHARMACOTHERAPY. Abingdon: TAYLOR & FRANCIS LTD, 2016, vol. 17, No 2, p. 283-295. ISSN 1465-6566. Available from: https://dx.doi.org/10.1517/14656566.2016.1135129.

Basic information

• Original name: Brivaracetam for the treatment of epilepsy
• Authors: KLEIN, Pavel (840 United States of America), Ivana TYRLÍKOVÁ (203 Czech Republic), Milan BRÁZDIL (203 Czech Republic) and Ivan REKTOR (203 Czech Republic, guarantor, belonging to the institution).
• Edition: EXPERT OPINION ON PHARMACOTHERAPY, Abingdon, TAYLOR & FRANCIS LTD, 2016, 1465-6566.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 3.894
• RIV identification code: RIV/00216224:14740/16:00090504
• Organization unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.1517/14656566.2016.1135129
• UT WoS: 000370165600001
• Keywords in English: Synaptic vesicle protein 2A ligand; Brivaracetam; anticonvulsant agent; partial-onset seizures; refractory epilepsy
• Tags: rivok

Abstract

Introduction: Approximately one third of patients with epilepsy fail to respond to existing medications. Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A. Brivaracetam is a novel high affinity SV2A ligand with approximately 20-fold higher affinity for SV2A protein than levetiracetam. It is at an advanced stage of clinical development for treatment of epilepsy.Areas covered: This article reviews animal data, pharmacokinetics, and phase 1-3 data of Brivaracetam treatment of epilepsy. Brivaracetam has broad-spectrum anticonvulsant activity in animal models.Expert Opinion: Phase 1 studies indicated that single oral doses of 5-800 mg and repeated oral doses of up to 600 mg were well tolerated and showed favorable pharmacokinetic profile. Phase 2 studies indicated good safety and tolerability of brivaracetam in the dose range of 5-150 mg/day and provided proof of concept for efficacy in treating refractory partial onset seizures. Efficacy and safety have been evaluated in 4 phase 3 studies with dose range of 5-200 mg which have demonstrated efficacy in the range of 100-200 mg/day dose and, in most studies, also with 50 mg/day dose, and good safety and tolerability profile across 5-200 mg doses in adjunctive treatment of refractory partial onset seizures.